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Over the past few decades understanding and recognition of hantavirus infection has greatly improved
worldwide, but both the amplitude and the magnitude of hantavirus outbreaks have been increasing.
Several novel hantaviruses with unknown pathogenic potential have been identiﬁed in a variety of
insectivore hosts. With the new hosts, new geographical distributions of hantaviruses have also been
discovered and several new species were found in Africa. Hantavirus infection in humans can result in
two clinical syndromes: haemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmo-
nary syndrome (HCPS) caused by Old World and New World hantaviruses, respectively. The clinical
presentation of HFRS varies from subclinical, mild, and moderate to severe, depending in part on the
causative agent of the disease. In general, HFRS caused by Hantaan virus, Amur virus and Dobrava virus
are more severe with mortality rates from 5 to 15%, whereas Seoul virus causes moderate and Puumala
virus and Saaremaa virus cause mild forms of disease with mortality rates <1%. The central phenomena
behind the pathogenesis of both HFRS and HCPS are increased vascular permeability and acute throm-
bocytopenia. The pathogenesis is likely to be a complex multifactorial process that includes contributions
from immune responses, platelet dysfunction and the deregulation of endothelial cell barrier functions.
Also a genetic predisposition, related to HLA type, seems to be important for the severity of the disease.
As there is no effective treatment or vaccine approved for use in the USA and Europe, public awareness
and precautionary measures are the only ways to minimize the risk of hantavirus disease. T. Avsic-
Zupanc, CMI 2016;▪:1
© 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Since its ﬁrst description in Chinese writings 900 years ago, the
disease resembling hantavirus infection came to the attention of
the world during the Korean conﬂict (1950e53). More than 3000
United Nations troops fell ill with Korean haemorrhagic fever,
which is commonly referred to as haemorrhagic fever with renal
syndrome (HFRS). However, the causative agent of the disease
remained unknown until the early 1980s, when Lee et al. reported
on Hantaan virus (HTNV), present in the lungs of its natural
reservoir, the striped ﬁeld mouse (Apodemus agrarius) [1]. Although
the milder form of HFRS, nephropathia epidemica (NE), has been
known in Fennoscandia since the early 1930s, its aetiological agent
Puumala virus (PUUV) was found in bank voles (Myodes glareolus)
in Finland only in 1980 [2]. Another important milestone oftute of Microbiology and
bljana, Slovenia.
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panc T, et al., Hantavirus infehantavirus infection was the outbreak that occurred in the Four
Corners region of the USA in 1993 with the disease called hanta-
virus cardiopulmonary syndrome (HCPS) [3]. The causative agent of
HCPS, Sin Nombre virus (SNV) and other pathogenic hantaviruses
including Andes virus (ANDV) have been reported in North and
South America [4].
Pathogenic hantaviruses, in nature carried by a speciﬁc rodent
host species, can cause severe disease in humans with mortality
rates from 12% (HFRS) [5] to 40% (HCPS) [6]. Both diseases are acute
febrile infections, usually acquired through inhalation of aerosols or
dust particles contaminated with virus containing rodent excreta
[7]. HFRS is characterized by renal failure and haemorrhagic man-
ifestations that vary from petechiae to severe internal bleeding.
Pneumonia and cardiovascular dysfunction are characteristics of
HCPS. Increased permeability of microvascular endothelium seems
to be a common effect of hantavirus infection. In the complex
pathogenesis of hantavirus infection it is suggested that not the
direct viral cytopathology, but immune mechanisms may play an
important role [8].of Clinical Microbiology and Infectious Diseases. This is an open access article under
ctions, Clinical Microbiology and Infection (2016), http://dx.doi.org/
Fig. 1. Hantavirus life cycle and spillover infection to humans. In nature hantaviruses
are circulating via horizontal transmission between chronically infected natural host
reservoirs (mice, rats, voles). Most human infections occur when contaminated aero-
solized rodent excreta are inhaled.
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ranging from acute renal failure to pulmonary oedema and severe
haemorrhagic illness, have been identiﬁed around theworld. While
around 1000 HCPS cases have been reported, it is estimated that
more than 100 000 HFRS cases occur worldwide each year. In many
countries hantaviral infections are undetected and not reported, so
additional hantaviruses may remain undiscovered. Hantaviruses
and the diseases they cause deserve the attention of researchers
and public health ofﬁcials, and increased clinician awareness with
regard to their impact on public health.
General properties of hantaviruses
Hantaviruses are enveloped RNAviruses, spherical in shapewith
a diameter of 80 to 120 nm, and they form a separate genus within
the Bunyaviridae family. The genome comprises three negative-
sense, single-stranded RNAs that share a 30 terminal sequence of
the genome segments. The three segments, S (small), M (medium)
and L (large), encode the nucleoprotein (N), envelope glycoproteins
(Gn and Gc), and the L protein or viral RNA-depended RNA poly-
merase, respectively [9]. Like other enveloped viruses, hantaviruses
are readily inactivated by heat (30 min at 60C), detergents, UV
irradiation, organic solvents and hypochlorite solutions. Hantavi-
ruses infect endothelial, epithelial, dendritic and lymphocyte cells
by the attachment of the viral glycoprotein to the cell surface re-
ceptors. Until now, it is considered that b1-integrin interacts with
viral Gn of apathogenic hantaviruses, while b3-integrin interacts
with the glycoprotein of pathogenic hantaviruses [10,11]. Hantavi-
ruses replicate in the cytoplasm and the glycoproteins are targeted
to the Golgi complex, where most hantaviruses bud. However, SNV
has been shown to bud at the plasma membrane [4]. Hantaviruses
found in Eurasia and in America share common features of their life
cycles, but based on recent studies it was suggested that they may
have evolved differently in speciﬁc interaction with the host cell
machinery [7].
Hantavirus ecology
In contrast to other Bunyaviruses, hantaviruses are not trans-
mitted by an arthropod vector, but are carried and transmitted to
humans by persistently infected rodent or insectivore hosts and
even bats (Fig. 1). Therefore, it is not surprising that the ecology and
geographical distribution of hantaviruses relate to the distribution
of their natural reservoir. The hantavirus prototype strain, HTNV,
was ﬁrst isolated from the striped ﬁeld mouse, Apodemus agrarius,
in 1976 [1]. The discovery of the aetiological agent of HFRS in South
Korea prompted research all over the world, which resulted in the
discovery of other HFRS-associated novel viruses in the Old World.
Hantaviruses have since been discovered to circulate not only in
Asia and Europe, but also in both Americas and Africa (detailed
review in refs [7,8]).
In general it is accepted that infection of the natural host is
inapparent and does not produce disease. Despite that, a few
studies have described some negative impact of hantavirus infec-
tion on the hosts' survival [12], the slower growth of infected ani-
mals [13,14] and the presence of histopathological changes in
infected tissues [15]. Understanding the ecology of hantaviruses
requires an interdisciplinary research approach, which links labo-
ratory experiments with results obtained from ﬁeld studies
involving wild-caught animals. Hantaviruses are usually closely
associated with a single rodent (insectivore) species, which is a
result of a co-evolution of the virus and the host [16]. The infection
of other animals such as moose [17], red fox [18], or domestic cat
and dog [19,20] is considered to be a spillover with minor or non-
existent risk for human infection [21]. But a spillover infection of aPlease cite this article in press as: Avsic-Zupanc T, et al., Hantavirus infe
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by complex biogeographic and anthropogenic pressures on the
environment (reviewed in ref. [7]). Because spillover infection en-
ables natural reassortment and origination of new hantavirus
species, this might also be important with regard to public health
[24].Old World hantaviruses
Several hantaviruses that have been demonstrated to circulate
in Europe and Asia belong to the so-called ‘OldWorld hantaviruses’,
and they are carried by animal species of four rodent generactions, Clinical Microbiology and Infection (2016), http://dx.doi.org/
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families: Soridae and Talpidae.
The most widely distributed rodent reservoir in Europe is the
bank vole Myodes glareolus, the carrier of PUUV [2], which inhabits
the whole continent with the exception of the Mediterranean re-
gion [4]. In Asia two other species of vole host hantaviruses:Myodes
rufocanus, the carrier of Hokkaido virus (HOKV) in Japan [25] and
Myodes regulus, carrier of Muju virus (MJUV) in Korea [26]. Despite
some seroprevalence studies the virulence towards humans of
HOKV and MJUV is still undetermined [26].
Another group of voles, from the genusMicrotus are populating
North America, Europe and Asia [27]. Namely, several hantavirus
serotypes have been isolated from Microtus spp. not only in
Europe: Khabarousk and Vladivostok virus isolated from Microtus
fortis [28,29] and Tula virus from Microtus arvalis and Microtus
levis (previously Microtus rossiaemeridionalis) [30], but also in
America: Prospect Hill virus fromMicrotus pennsylvanicus [31], Isla
Vista virus from Microtus californicus [32] and Bloodland Lake vi-
rus from Microtus ochrogaster [33]. In Siberia a hantavirus is hos-
ted by lemmings, called Topografov virus isolated from Lemmus
sibiricus in 1996 [34]. Although, there is some evidence of possible
human infection with Tula virus [35,36] currently no clinical dis-
ease has been clearly associated with any Microtus-carried han-
taviruses [37].
A severe form of HFRS is related with Apodemus mouse-borne
hantaviruses in Asia and Europe. In Asia the presence of HTNV
and HTNV-like viruses (Amur/Soochong virus) was demonstrated
in Apodemus agrarius and Apodemus peninsulae in Far East Russia,
China and South Korea [38e40]. On the other hand, the Apodemus
mice are also widely spread in Europe hosting different hanta-
viruses, which reveals a complex ecology and evolution. The se-
vere form of HFRS, with high mortality rate, was reported in the
Balkan region in the early 1950s. The etiologic agent, Dobrava
virus (DOBV) was characterized in 1992, after isolation from its
rodent host Apodemus ﬂavicollis captured in Dobrava village,
Slovenia [41]. Later, a new DOBV-like virus was isolated from
A. agrarius captured in Tula region in European Russia [42]. Mo-
lecular and phylogenetic analyses have shown that this is a new
lineage of DOBV, named DOBV-Aa, which causes a mild to
moderate form of HFRS in Central Europe [43,44]. Another DOBV-
like isolate was recovered from A. agrarius captured on the
Saaremaa island of Estonia [45]. This new genetic lineage was
also accepted as a new virus species, named Saaremaa virus
(SAAV) [46], after it was found in a natural reservoir in several
different European countries [5]. Until now, infection with SAAV
has been conﬁrmed using serological methods in only three HFRS
patients, albeit no molecular evidence has yet been postulated
[47]. In addition, a fourth lineage of DOBV-like virus was detected
in Apodemus ponticus from Sochi district, Russia [48]. It is unusual
for a hantavirus, but DOBV has already been found in three
different Apodemus species and although all lineages share high
amino acid sequence similarity, they can be separated phyloge-
netically and also seem to possess different virulence towards
humans [48].
Another hantavirus is present worldwide, Seoul virus (SEOV)
harboured by Rattus norvegicus [49]. Its global distribution is the
result of host dispersion all over the world. In Europe, SEOV
persistence was demonstrated in a population of R. norvegicus
captured in France, but no human infection in Europe has been
reported [50]. In contrast to other hantaviruses, SEOV experienced
only a minor geographical variation [7,51]. In Asia distinct lineages
of SEOV-related hantaviruses were found: Gou virus, harboured by
Rattus rattus [52], Serang virus is carried by Rattus tanezumi [53]
and Thailand virus, from Bandicota indica [54].Please cite this article in press as: Avsic-Zupanc T, et al., Hantavirus infe
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A second group of hantaviruses are so-called ‘New World
hantavirus’, which were ﬁrst recognized in 1993, after an outbreak
of an acute pulmonary distress syndrome in America. The causative
agent was named SNV and isolated from the common deer mouse,
Peromyscus maniculatus [3]. Soon after, many new hantaviruses
were isolated from different mice and rats inhabiting the Americas
[55]. In South America, the most important hantavirus is ANDV,
which is themain causative agent of HCPS in Argentina [56] and the
only hantavirus for which an ability to spread from human to hu-
man has been described [57,58]. Altogether, there are more than 30
new hantavirus strains and genetic lineages throughout the
Americas, which have been recently review in detail by Jonsson
et al. [7].
Insectivore-borne hantaviruses
Although several studies have shown the presence of antibodies
that cross-react with Eurasian hantaviruses in African populations,
until 2006 the African continent was a blank spot on the hantavirus
map [59]. The ﬁrst African hantavirus was named Sangassou virus
and was found in Africanwoodmouse, Hylomyscus simus [59]. Soon
after that, another African hantavirus (Tanganya virus) was isolated,
surprisingly from a shrew host, Crocidura theresae, in Guinea [60].
For a long time hantaviruses were believed to be rodent-borne
pathogens, but since 2006 several new shrew and mole-borne
hantaviruses have been discovered. Above that, historically the
ﬁrst discovered hantavirus, Thottapalayam virus, in 1964, was iso-
lated from Asian house shrew (Suncus murinus) and was placed in
the genus Hantavirus, based on its morphological features [61,62].
Besides Africa and Asia, also in Europe several insectivores were
identiﬁed as hantavirus hosts. The most spread shrew-borne
hantavirus in Europe is Seewis virus, ﬁrst isolated from Sorex ara-
neus in Switzerland [63]. Shortly thereafter, Seewis virus was found
in different Sorex sp. in several countries in Europe [64e66].
Nothing is known about the pathogenicity of shrew-borne or mole-
borne hantaviruses, but concerning the low amino acid similarities
between rodent- and shrew-borne hantaviruses this is not a sur-
prise (reviewed in ref. [8]). The ﬁrst serological assay to detect
Thottapalayam virus has shown the presence of antibodies in a
febrile patient in Thailand [67]. Finally, we can conclude that
additional research will reveal hantavirus evolution and signiﬁ-
cance for human health.
Quite recently, hantaviruses were molecularly detected in bats
from Sierra Leone and Cote d'Ivoire [68,69]. Even though hantavi-
ruses detected in bats are distinct from other hantaviruses, the role
of bats as novel hosts or as spillover infection is still under research.
Nonetheless, these ﬁndings underline the complex evolutionary
history of hantaviruses.
Hantavirus phylogeny
Hantaviruses are associated with their natural reservoir hosts,
mainly rodents, but also insectivores (shrews and moles) and bats.
The chronically and probably asymptomatically infected animals
may excrete the virus in their urine, faeces and saliva for months.
The genetic and serological relation of hantaviruses follows that of
their natural reservoir; these viruses have probably coevolved with
their rodent hosts for millions of years [70]. They are considered to
be one of the best examples of a long-term association between
RNA virus and the host. However, some analyses have proposed
that similarities between the phylogenies of hantaviruses and their
natural hosts are a result of a more recent history, probably a result
of host switching and local adaptation, rather than joint host andctions, Clinical Microbiology and Infection (2016), http://dx.doi.org/
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tween closely related rodent species, recent ﬁndings on
insectivore-associated hantaviruses call for revaluation of the co-
divergence concept [72].
The association between hantaviruses and their natural hosts
reﬂects also in their phylogeny. Rodent-associated hantaviruses
form three major evolutionary clades that correspond to the three
Muridae subfamilies of their natural hosts. Phylogenetic analyses
show that the viruses carried by Arvicolinae (voles), Sigmondon-
tinae (New World rats and mice) and Murinae (Old World rats and
mice) rodent subfamilies each form a separate branch. Insectivore-
associated hantaviruses and their carriers from families Sorcidae
(shrews) and Talpidae (moles) form a fourth evolutionary clade.
Bioinformatics analysis of a hantavirus recently detected in an Af-
rican insectivorous bat, Nycteris hispida (family Nycteridae),
showed high degrees of identity to shrew- and mole-associated
hantaviruses. The genetic variation within a certain hantavirus
type is related to geographic distribution and distance, which may
depend on the ancestral migration routes of the corresponding
rodent reservoir [4]. Recently, several novel hantaviruses with
unknown pathogenicity for humans have been identiﬁed in Africa
in a variety of insectivores. These insectivore hantaviruses share
very low amino acid sequence similarity with rodent-borne han-
taviruses and consequently probably no serological cross-reactivity
either. This explains why they have remained undiscovered for
such a long period [8].Epidemiology of hantavirus infections
Humans do not belong to the natural host range of hantaviruses,
and infection generally occurs accidentally by inhalation of virus-
containing aerosols from rodent excretions such as urine, faeces
and saliva [73,74]. Although the aerosol route of infection isTable 1
List of medically important hantaviruses
Group Virus Geographic distribution
Old World hantaviruses Amur/Soochong Far East Russia
Dobrava Balkans
Hantaan Russia, China, South Korea
Puumala Europe, Asia
Luxi China
Saaremaa Europe
Seoul South Korea
Tula Europe, Russia
Anajatuba South America
Araucaria South America
Araraquara Brazil
Bayou North America
Bermejo Argentina
Black Creek Canal North America
Castelo dos sonhos South America
Choclo Panama
Itapua South America
Juquitiba Brazil
Laguna Negra Argentina, Bolivia, Paraguay
Lechiguanas Argentina
Maporal South America
Monongahela North America
Neembucu South America
New York North America
Oran Argentina
Paranoa South America
Rio Mamore Bolivia, Peru
Sin Nombre North America
HCPS, hantavirus cardiopulmonary syndrome; HFRS, haemorrhagic fever with renal syn
* Association with the disease not deﬁnitely conﬁrmed.
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has also been reported [75]. Person-to-person transmission was
considered unlikely until 1996, when reports regarding trans-
mission of ANDV in an HCPS outbreak in Argentina changed this
perception [76,77].
The risk of contracting hantavirus from rodents is related to
closeness of contact. People who live or work in close contact with
infected rodents are at increased infection risk, with occupations
such as animal trappers, mammalogists, forestry workers, farmers
and military personnel at highest risk [78e80]. Humans are usually
infected from aerosolized rodent excreta when working with hay
and crops during harvesting, cuttingwood inside dusty woodsheds,
cleaning cellars, barns, sheds or summer cottages in the autumn,
especially when these spaces are poorly ventilated [5].
The time and space distribution of hantavirus infections in man
mirror the distribution of their rodent hosts. Hence HFRS cases are
reported in Europe and Asia, while HCPS has only been described in
the Americas, with different hantaviruses being found where their
hosts predominate [7,73]. Today, approximately 100 000 HFRS
cases are estimated to occur annually, with China being the most
endemic country, accounting for 70e90% of all HFRS cases
(40 000e60 000 cases annually in the past few years) [81,82]. It
should however be kept in mind that asymptomatic or non-speciﬁc
mild infections probably outnumber the symptomatic, character-
istic infections. In addition, hantavirus disease is not notiﬁable in all
the countries where clinical cases occur [5].Epidemiology of HFRS in Eurasia
Seven hantaviruses have been associated with HFRS so far
(Table 1). In Asia severe cases of HFRS are caused by HTNV and
Amur/Soochong virus, with mortality rates up to 15%, whereas in-
fections with SEOV result in moderate disease course with caseRodent carrier Disease
Apodemus peninsulae HFRS
Apodemus ﬂavicollis HFRS
Apodemus agrarius HFRS
Myodes glareolus HFRS (NE)
Eothenomys miletus HFRS
Apodemus agrarius HFRS
Rattus HFRS
Microtus arvalis HFRS*
Oligoryzomys fornesi HCPS
Oligoryzomys nigripes, Oxymycterus judex, Akodon montensis HCPS
Bolomys lasiurus HCPS
Oryzomys palustris HCPS
Bolomys lasiurus HCPS
Sigmodon hispidus HCPS
Oligoryzomys eliurus HCPS
Oligoryzomys fulvescens HCPS
Oligoryzomys nigripes HCPS
Oligoryzomys nigripes HCPS
Calomys laucha HCPS
Oligoryzomys ﬂavescens HCPS
Oligoryzomys delicatus HCPS
Peromyscus leucopus HCPS
Oligoryzomys chacoensis HCPS
Peromyscus leucopus HCPS
Oligoryzomys longicaudatus HCPS
Not known HCPS
Oligoryzomys microtis HCPS
Peromyscus maniculatus HCPS
drome; NE, nephropathia epidemica.
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reported, 99% of them from China [7,73,83].
In Europe, more than 9000 HFRS cases per year are reported,
with PUUV infections being the most predominant. In general,
PUUV infections occur throughout central and northern Europe, the
Balkans and Russia within the range of theMyodes glareolus habitat
and result in a mild form of HFRS, known as NE. Most PUUV-
associated cases have been diagnosed in parts of European Russia,
Finland and Sweden. In recent years NE has been fairly common
also in Belgium and Germany, followed by Norway, France,
Hungary, Austria, Slovenia and others [4,5,84].
Severe cases of HFRS in Europe are caused by DOBV, carried by
A. ﬂavicollis, and have so far been identiﬁed only in the Balkan re-
gion, although the host distribution is much wider [85e89].
SAAV (and/or DOBV-Aa) carried by A. agrarius has been
recognized as a distinct causative agent of a mild form of HFRS,
reported in Russia, Germany and Slovakia [35,48,90,91]. In
contrast to DOBV-HFRS cases in the Balkans, where mortality rates
up to 12% have been reported [86], and no fatal cases were asso-
ciated with the SAAV caused HFRS. Recently, another lineage of
DOBV was identiﬁed in A. ponticus in the Sochi region in European
Russia and was associated with a moderate-to-severe form of
HFRS [48]. The broad spectrum of clinical diseases caused by the
four different DOBVs, despite their close genetic resemblance,
could perhaps be explained by the three different rodent species
that represent their natural reservoirs.
Tula virus has been associated with human infections in the
Czech Republic, Switzerland and Germany, but this association has
not been unequivocally demonstrated [35,36,92].
Through in sero-epidemiological surveys, human hantavirus
infections have also been reported in Italy [93], Latvia [94],
Lithuania [95], Moldova [96], Spain [97] and the UK [98], but no
clinical cases have been registered in these countries.Epidemiology of HCPS in the Americas
Since HCPS was ﬁrst recognized as a hantaviral disease in the
Four Corners area in May 1993, clinical cases have also been
conﬁrmed in Argentina, Bolivia, Brazil, Canada, Chile, Panama,
Paraguay and Uruguay and at least 15 hantaviruses have been
associated with HCPS. Approximately 200 cases of HCPS per year
are reported jointly in North and South America. Even though the
number of reported cases is considerably smaller than that of HFRS,
the average case fatality in HCPS is around 40%. SNV is now known
to be the predominant cause of HCPS in the USA, whereas in South
America the most important causative agent is ANDV [7,99]. ANDV
is so far also the only hantavirus with reported person-to-person
transmission with high mortality rates [57,58,77,100]. In addition,
it has been suggested that HCPS-associated viruses, like HFRS-
causing viruses, may cause unrecognized, asymptomatic or sub-
clinical infections. Namely, a high prevalence of antibodies against
HCPS-causing hantaviruses was reported in some populations
despite rare clinical cases [101,102].Hantavirus infection in Africa
In Africa, the ﬁrst serological evidence of hantavirus infections
was obtained in 1984, when Gonzalez et al. demonstrated hanta-
virus antibodies in humans and rodents in Benin, Burkino Faso,
Central African Republic and Gabon [103]. Since then, human
hantavirus infections have been demonstrated through serological
surveys also in Senegal, Nigeria, Egypt, Djibouti and Guinea
[104e108]. However, only a single case of possible HFRS in Africa
has been reported in the literature to date [109].Please cite this article in press as: Avsic-Zupanc T, et al., Hantavirus infe
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Hantavirus infection in humans can result in two clinical syn-
dromes: HFRS or HCPS caused by Old World or New World han-
taviruses, respectively. The differences between the hantavirus-
associated diseases are caused by the fact that different vascular
beds are predominantly affected, namely renal medulla capillaries
during HFRS and pulmonary capillaries during HCPS. On the other
hand, the initial symptoms of all hantavirus infections are similar,
including an abrupt onset of high fever, malaise, myalgia and other
ﬂu-like symptoms. Common factors of HFRS and HCPS are also
increased vascular permeability leading to hypotension, thrombo-
cytopenia and leucocytosis with a left shift [21,55,110].
Hemorrhagic fever with renal syndrome
The clinical presentation of HFRS varies from subclinical, mild,
andmoderate to severe, depending in part on the causative agent of
the disease. In general, HFRS caused by HTNV, Amur/Soochong
virus or DOBV are more severe with mortality rates from 5 to 15%,
whereas SEOV causes moderate disease and PUUV and SAAV cause
mild forms of disease with mortality rates <1%. Nevertheless, an
individual case of PUUV infection may be severe, an individual
HTNV infection may be mild, and infections are commonly sub-
clinical seroconversion [7,111,112].
A typical course of HFRS can be divided into ﬁve distinct phases:
febrile, hypotensive, oliguric, polyuric and convalescent (Fig. 2).
These phases are better distinguished in severe forms of disease
caused by HTNV and DOBV. After an incubation period between 2
and 4 weeks, the disease starts abruptly with high fever, chills,
headache, backache, abdominal pains, nausea and vomiting. Som-
nolence and visual disturbances (blurred vision) are frequently
reported. This febrile phase usually lasts 3 to 7 days. Towards the
end of this phase conjunctival haemorrhages and ﬁne petechiae
occur initially on the palate. The hypotensive stage can last from
several hours to 2 days. In severe cases, hypotension, even shock,
may develop rapidly and one-third of HFRS deaths are associated
with fulminant irreversible shock at this stage. Thrombocytopenia
and leucocytosis are characteristic of this phase and if severe hae-
morrhagic disease occurs, its onset is at this stage. Haemorrhagic
manifestations can include petechiae on the skin and mucosa, ec-
chymoses, conjunctival suffusion, haematemesis, epistaxis, hae-
maturia, melaena and fatal intracranial haemorrhages. In the
oliguric phase, which lasts 3e7 days, blood pressure becomes
normalized, while kidney function is transiently decreased, leading
to oliguria or even anuria, proteinuria, abnormal urinary sediment,
including microscopic haematuria, and azotaemia. During the oli-
guric phase, which is usually accompanied by abdominal or back
pain, patients with severe symptoms have to be treated by hae-
modialysis. One-half of fatalities occur during this phase. Typical
laboratory ﬁndings are elevated levels of serum creatinine and
urea. In the polyuric phase, renal function starts to recover and
urinary output increases. The onset of the diuretic phase is a pos-
itive prognostic sign for the patient. It can last for days or weeks
with patients passing several litres of urine per day. Convalescence,
characterized by recovery of clinical and laboratory markers, is
usually prolonged and can last for up to 6 months. Full recovery is
usually reached and longer-lasting complications are rare but can
include chronic renal failure and hypertension [98,111,113]. In
children, the clinical picture closely mimics that in adults but is
often less severe. However, abdominal manifestations are regis-
tered more often [114e116].
In milder forms of HFRS caused by SEOV, A. agrarius-associated
DOBV (DOBV-Aa), SAAV or in NE caused by PUUV the ﬁve phases of
HFRS are not easily distinguishable. The clinical picture of PUUVctions, Clinical Microbiology and Infection (2016), http://dx.doi.org/
Fig. 2. Schematic representation of hantavirus infection kinetics with a clinical course of the disease in humans. A typical course of haemorrhagic fever with renal syndrome (HFRS)
can be divided into ﬁve distinct phases: febrile, hypotensive, oliguric, polyuric and convalescent. After the infection viral load starts to peak and with the onset of the ﬁrst clinical
symptoms, the antibodies rise. Hallmark laboratory ﬁndings that are substantial with development of HFRS are decreases in platelets and urine output and increase in serum
creatinine level.
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of symptoms resulting in lower mortality rates (0.1%). In NE, severe
haemorrhagic manifestations and shock usually do not occur, but
mild haemorrhagic symptoms such as petechiae are seen in about
one-third of patients. Instead of full-blown shock syndrome, hy-
potension is observed. Although most patients have signs of kidney
function failure, it is generally less prominent than in HFRS caused
by more virulent hantaviruses, with oliguria or anuria manifesting
in less than half of the patients. Altogether, since the clinical course
of NE is often uncharacteristic and resembles more a febrile disease
with abdominal pain, it is often not diagnosed as NE [117,118].
Infection with SEOV causes a moderate form of HFRS with
clinical presentation and course very similar to HFRS caused by
HTNV. However, SEOV infections are often associated with the
presence of hepatitis, which is generally not present in other
hantavirus infections [113,119].Hantavirus cardiopulmonary syndrome
In comparison with HFRS, HCPS is a more severe disease with
higher case fatality rates, from about 30 to 50%. The clinical course
of HCPS generally progresses through three phases: prodromal,
cardiopulmonary and convalescent, and clinical manifestations can
vary from mild hypoxaemia to respiratory failure with cardiogenic
shock [120].
The prodromal phase is usually a short non-speciﬁc illness with
ﬂu-like symptoms such as high fever, chills, myalgia, nausea,
headache, vomiting, abdominal pain and diarrhoea. This is followed
by a rapid progression to the cardiopulmonary phase with abrupt
onset of progressive cough, shortness of breath and tachycardia.
Patients develop acute non-cardiac pulmonary oedema and hypo-
tension. Bilateral inﬁltrates develop rapidly, sometimes associated
with pleural effusions, causing respiratory failure and making
mechanical ventilation mandatory. In severe cases this stage is
complicated by cardiogenic shock, lactic acidosis and massive
haemoconcentration. Patients can die within hours of hospitaliza-
tion. Patients who survive the acute phase of the disease enter the
polyuric stage, which is accompanied by the resolution of the
pulmonary oedema. Although convalescence is slow and patientsPlease cite this article in press as: Avsic-Zupanc T, et al., Hantavirus infe
10.1111/1469-0691.12291often complain about weakness, fatigue and impaired exercise
tolerance, the recovery is generally complete, without any sequelae
[99,110,120].
Although renal disease is usually assigned to HFRS and lung
disease to HCPS, the increased medical knowledge about the clin-
ical courses of HFRS and HCPS has resulted in the conclusion that
both syndromes partly overlap. Namely, the numbers of reported
HFRS cases with lung involvement and HCPS cases with renal and/
or haemorrhagic involvement are continuously growing [121e123].Hantavirus pathogenesis
In both animals and humans hantavirus infections mainly occur
in pulmonary or renal endothelial cells andmacrophages, albeit the
viral antigen is present also in many different organs [124,125]. In
contrast to humans, animals tend to be persistently infected
throughout their entire lifespan and still capable of transmitting
the virus to other animals and humans. Therefore, the lack of
apparent disease in the natural host and the lack of proper animal
models have limited our understanding of hantavirus pathogenesis
[126]. Until recently, there was no animal model for HFRS, because
the Syrian hamster model used for ANDV and HCPS [127] is not
applicable to HFRS. However, cynomolgus monkeys infected with
wild-type PUUV strains produce disease symptoms that resemble
NE clinical pathology [128,129].
The central phenomena behind the pathogenesis of both HFRS
and HCPS are increased vascular permeability and acute throm-
bocytopenia with marked permeability of microvascular beds
[11,130]. Hantavirus replication occurs in the vascular endothelium
but does not seem to cause direct cytopathic effects [131e133]. The
hantavirus replication cycle is rather slow, resulting in late viraemia
on days 5 to 10 after infection [134], which would suggest virus
persistence rather than the acute lytic progression seen in other
viral haemorrhagic fevers [11]. In human kidney tissues of patients
with NE the viral antigen was detected along with inﬂammatory
cell inﬁltrations and tubular damage, suggesting that viral repli-
cation together with the immune response are involved in tissue
injury [133,135]. The peritubular area of the distal nephron is the
main site where an increased expression of several cytokines andctions, Clinical Microbiology and Infection (2016), http://dx.doi.org/
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ment in acute NE is characterized by markedly decreased glomer-
ular ﬁltration rate and renal plasma ﬂow. Increased glomerular
permeability leads to massive proteinuria and is a sign of tubular
dysfunction [136].
It is not yet completely understood how hantaviruses
disseminate in the human body, after inhalation, the infection
begins with an interaction of Gn and Gc surface proteins with b-
integrin receptors at the target cell membrane [137,138]. It has
been shown that both pathogenic (HTNV, SEOV, PUUV, SNV) and
non-pathogenic (Tula virus, Prospect Hill virus) hantaviruses
infect human endothelial cells, but they use a different integrin
receptor (avb1 versus a5 b3) [137]. Probably immature dendritic
cells play a pivotal role in hantavirus dissemination, as they ex-
press b3-integrin receptors and are located in the vicinity of
epithelial cells [139]. They can also serve as vehicles for the
transport of the virions through the lymphatic vessels to the
regional lymph nodes, where after further replication virions can
reach endothelial cells [110]. These cells allow virus replication,
which induces immune activation, especially by macrophages
and CD8þ T cells [7]. It has been shown that a type I interferon
response has been delayed in cells infected with pathogenic
hantaviruses, resulting in higher viral titres [110]. Inﬂammatory
cytokine and chemokines produced by antiviral innate immune
response can act as double-edged sword. Increased levels of
interleukin-10, interferon-g and tumour necrosis factor-a in
serum samples were found in both DOBV- and PUUV-infected
patients. In addition, the signiﬁcantly higher levels of
interleukin-10 and tumour necrosis factor-a were detected in
patients with a more severe clinical course of the disease [140]. In
NE patients the disease severity is characterized by elevated pro-
inﬂammatory cytokines interleukin-6 and tumour necrosis fac-
tor-a, but low immunosuppressive transforming growth factor-b1
levels. The upregulation of transforming growth factor-b1 in the
late phase of acute PUUV infection suggests a protective immu-
noregulatory role [141]. In NE patients cytotoxic T cells may
contribute to the capillary damage via immunopathology, also by
increased concentrations of nitric oxide and tumour necrosis
factor-a [142,143]. In contrast with other haemorrhagic fever vi-
ruses, which inhibit maturation of infected dendritic cells, han-
taviruses induce their maturation and so elicit a vigorous T-cell
response during acute infection [144]. In NE patients the cyto-
toxic T-lymphocyte response enhanced the number of activated
CD8þ T cells and reversed CD4þ versus CD8þ T-cell ratio, which
coincides with the onset of clinical disease [145e147]. A mixed
pattern of T helper type 1 and T helper type 2 immune response
patterns, high levels of proinﬂammatory cytokines and their
insufﬁcient suppression by regulatory cytokines leads to the
harmful effect of immune response in HFRS-infected patients
[110]. Hantavirus pathogenesis is likely to be a complex multi-
factorial process that includes contributions from immune re-
sponses, platelet dysfunction and the deregulation of endothelial
cell barrier functions [11]. Above that, a genetic predisposition
towards severe HFRS disease was shown to be related to HLA
type, but different hantaviruses were associated with different
HLA haplotypes. A genetic predisposition towards a severe form
of HFRS caused by PUUV infection was shown to be associated
especially with haplotype HLA-B*8 DRB1*03:02 [148e151]. The
same HLA haplotype was again correlated with a severe course of
HCPS after ANDV infection [152]. In addition, HLA haplotype HLA-
B*35 was more frequent in severe disease progression in patients
infected with DOBV, especially in fatal cases [151]. The same HLA
type has already been reported in correlation with a severe form
of HCPS induced by SNV [144].Please cite this article in press as: Avsic-Zupanc T, et al., Hantavirus infe
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The diagnosis of HFRS and HCPS is based on clinical and
epidemiological data and laboratory tests. The symptoms that
should alert the physician to a possible hantavirus infection are
high fever, headache, abdominal and back pains and pathological
laboratory ﬁndings with leucocytosis, thrombocytopenia, increased
serum creatinine, proteinuria and haematuria. However, it is almost
impossible to diagnose hantavirus infections solely on clinical
grounds, especially in cases with mild and moderate clinical
symptoms, as the early signs of the disease are non-speciﬁc [5,73].
Laboratory diagnosis of acute hantavirus infections is based on
serology as virtually all patients have IgM and usually also IgG
antibodies present in serum at the onset of symptoms. The most
commonly used serological tests are indirect IgM and IgG ELISA as
well as IgM capture ELISAs, which have higher speciﬁcity than in-
direct ELISAs. Indirect immunoﬂuorescence assays are also regu-
larly used for diagnostics but have lower speciﬁcity [113,153]. In
addition, rapid 5-minute user-friendly immunochromatographic
IgM-antibody tests have been developed and are available
commercially [154,155].
The hantavirus infection can also be conﬁrmed by detection of
hantavirus genome in blood or serum samples by RT-PCR. Both
traditional and quantitative RT-PCR are used to detect viraemia
[156e158]. Although the presence of viraemia varies, viral RNA can
usually be detected if an acute sample is available. It has also been
suggested that higher viraemia is found in more severe hantavirus
infections (DOBV, SNV, ANDV), compared with milder infections,
caused by PUUV [134,150,159e161]. In addition, with detection of
viral RNA, hantavirus infection has been conﬁrmed even before the
presence of speciﬁc antibodies [100,159].
At present, no speciﬁc U.S. Food and Drug Administration-
approved therapy is available for either HFRS or HCPS; the treat-
ment is primarily supportive. It is recommended that patients with
HCPS and severe HFRS should be moved to an intensive care unit
for close monitoring and care. Maintaining the ﬂuid and electrolyte
balance together with circulatory volume is very important and
must be carefully monitored according to the patient's ﬂuid status,
amount of diuresis and kidney function to avoid dangerous over
hydration (for patients that are anuric and with leaky capillaries).
HFRS patients with severe renal insufﬁciency, which is associated
with severe ﬂuid retention and pulmonary oedema, may need
dialysis treatment. If extensive thrombocytopenia and bleeding are
present, platelet transfusions can be used [99,111,120]. In HCPS,
supplemental oxygen, mechanical ventilationwhen indicated, ﬂuid
management, and the appropriate use of pressors are crucial [99].
Ribavirin was shown to possess anti-hantaviral activity in vitro
and in vivo and was proven effective in treatment of suckling mice
infected with HTNV [162]. Ribavirin has been used in the treatment
of HFRS in China and clinical studies on Chinese HFRS patients
suggest that ribavirin therapy can signiﬁcantly reduce themortality
rate if given in the ﬁrst 5 days after onset of symptoms [163,164]. In
a recent report by Rusnak et al., it has been conﬁrmed that
administration of intravenous ribavirin early in the course of HFRS
reduces the occurrence of oliguria and the severity of renal insuf-
ﬁciency [165]. Intravenous ribavirin has also been examined for the
treatment of HCPS. However, in a few limited trials treatment with
ribavirin had no clinical beneﬁt for the patients [166,167].
Prevention
One of the major risk factors for infection is living close to
forested areas and cleaning up around houses or sheds [168]. In
addition, occupational exposures, such as construction or forest
workers, farmers and soldiers are at increased risk [80,168e170].ctions, Clinical Microbiology and Infection (2016), http://dx.doi.org/
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reducing rodents' shelter and food sources near human housing,
eliminating rodents inside homes and avoiding contact with
potentially contaminated areas. Apart from using standard pre-
caution measures, the only way of minimizing the risk of hanta-
virus disease could be effective vaccines, but up to now no vaccines
were approved for wide use in Europe or the USA. In Asia, the Re-
public of Korea, Hantavax® has been used for a number of years. The
vaccine is derived from formalin-inactivated HTNV-infected suck-
ling mouse brain, but frequent booster doses are needed for pro-
tective immunity [171]. In China, several different formalin-
inactivated vaccines from animal tissues have been produced and
used, but none has been approved for use in European countries
(reviewed in ref. [172]). Apart from that, only two molecular vac-
cines against HFRS have been tested in humans, the ﬁrst was re-
combinant vaccinia-vectored vaccine expressing the M segment of
HTNV [173] and the second plasmid DNA [174]. The advantage of
DNAvaccines is that they offer an easy way to construct multivalent
vaccines and they are able to induce long-lasting humoral and
cellular immunity. Such vaccine, using an M segment construct of
HTN and PUUV, is currently in Phase I clinical trials in the USA to
determine the safety, tolerability and immunogenicity [175,176].
Conclusions
Hantavirus infections belong to the increasing group of
emerging zoonotic infectious diseases. Over the past few decades
the understanding and recognition of hantavirus infection has
greatly improved worldwide. Both, the amplitude and the magni-
tude of hantavirus outbreaks have been increasing. This could be
explained by better clinical awareness, development of sensitive
diagnostic tests, intensive research on reservoir and changing cli-
matic conditions. Although some are newly detected, hantaviruses
are old viruses, but environmental changes may affect the
geographic distribution, abundance and the dynamic of the carrier
rodent species, and hence the epidemiology of hantavirus disease.
Although, today we can only speculate how extensive environ-
mental and climatic changes will be, hantavirus infections will
remain a public health threat. Therefore, further research on
hantavirus pathogenesis, diagnostics, antiviral and vaccine devel-
opment are needed.
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